Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 7.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,956 shares of the medical research company’s stock after purchasing an additional 204 shares during the period. J.W. Cole Advisors Inc.’s holdings in Edwards Lifesciences were worth $273,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. DSM Capital Partners LLC acquired a new position in Edwards Lifesciences during the fourth quarter worth approximately $28,000. Crewe Advisors LLC acquired a new position in Edwards Lifesciences during the first quarter worth approximately $28,000. First Community Trust NA acquired a new position in Edwards Lifesciences during the second quarter worth approximately $29,000. Riverview Trust Co acquired a new position in Edwards Lifesciences during the first quarter worth approximately $34,000. Finally, Pingora Partners LLC acquired a new position in Edwards Lifesciences during the fourth quarter worth approximately $38,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.4 %

NYSE EW opened at $67.53 on Thursday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. The company has a market capitalization of $40.69 billion, a price-to-earnings ratio of 29.11, a price-to-earnings-growth ratio of 2.85 and a beta of 1.13. The company’s fifty day moving average price is $70.89 and its two-hundred day moving average price is $83.11.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. The company had revenue of $1.63 billion for the quarter, compared to analysts’ expectations of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm’s revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.66 earnings per share. As a group, research analysts predict that Edwards Lifesciences Co. will post 2.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total transaction of $466,450.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total transaction of $466,450.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,250 shares of company stock valued at $1,218,138. Company insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on EW. Wells Fargo & Company dropped their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Piper Sandler dropped their price objective on shares of Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating for the company in a research report on Thursday, July 25th. JPMorgan Chase & Co. lowered shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $105.00 to $72.00 in a research report on Thursday, July 25th. UBS Group dropped their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Tuesday, September 10th. Finally, StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. Sixteen investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $79.82.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.